HHS awards $103.5M contract to Modex Therapeutics for multispecific antibody development against COVID-19 and avian flu

Contract Overview

Contract Amount: $103,516,903 ($103.5M)

Contractor: Modex Therapeutics, Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2023-09-27

End Date: 2028-02-29

Contract Duration: 1,616 days

Daily Burn Rate: $64.1K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA.

Place of Performance

Location: NATICK, MIDDLESEX County, MASSACHUSETTS, 01760

State: Massachusetts Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $103.5 million to MODEX THERAPEUTICS, INC for work described as: ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA. Key points: 1. Contract focuses on developing advanced countermeasures for significant public health threats. 2. Research and Development in Biotechnology sector, specifically targeting infectious diseases. 3. Long-term contract duration suggests a phased development and testing approach. 4. Awarded under full and open competition, indicating a broad search for qualified contractors. 5. Cost Plus Fixed Fee contract type allows for flexibility in research but requires careful cost management. 6. Potential for significant public health impact through improved preparedness. 7. Contractor's success hinges on achieving technical milestones in antibody development.

Value Assessment

Rating: good

The contract value of $103.5 million over approximately 4.5 years for advanced biotechnology research appears reasonable given the complexity and potential impact of developing novel multispecific antibodies. Benchmarking against similar R&D contracts in the biodefense and infectious disease preparedness space would provide further context, but the scope suggests a significant investment in a critical area. The Cost Plus Fixed Fee structure necessitates close monitoring of expenditures to ensure value for money.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, suggesting that the government actively sought proposals from a wide range of qualified entities. The number of bidders is not specified, but the open competition process generally promotes a competitive environment, which can lead to better pricing and innovative solutions. This approach is ideal for complex R&D where diverse expertise might be available.

Taxpayer Impact: Taxpayers benefit from a competitive process that aims to secure the best value and most effective solutions for critical public health research, potentially leading to more efficient use of funds.

Public Impact

The primary beneficiaries are the public, through enhanced preparedness against future pandemics and influenza outbreaks. Services delivered include the research and development of advanced, cross-reactive multispecific antibodies. Geographic impact is national, aiming to bolster U.S. public health security. Workforce implications include potential job creation in biotechnology research and development within the contractor's organization.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Cost overruns are a risk in Cost Plus Fixed Fee R&D contracts if not managed diligently.
Technical feasibility and success rates in developing effective antibodies can be uncertain in early-stage research.
Reliance on a single contractor for this critical development phase requires robust oversight.

Positive Signals

Focus on critical public health threats (COVID-19, avian flu) aligns with national security priorities.
Full and open competition suggests a thorough vetting process for potential solutions.
Long-term contract duration allows for sustained effort in a complex R&D endeavor.

Sector Analysis

This contract falls within the Biotechnology Research and Development sector, a rapidly evolving field critical for national biodefense and public health. The market for infectious disease countermeasures is substantial, driven by ongoing threats and government investment in preparedness. Comparable spending benchmarks would likely be found in other federal R&D awards for vaccine and therapeutic development, often ranging from tens to hundreds of millions of dollars depending on the stage and scope of research.

Small Business Impact

The contract was not awarded as a small business set-aside, and there is no explicit indication of subcontracting plans for small businesses in the provided data. This suggests that the primary focus was on securing specialized expertise for advanced biotechnology research, potentially favoring larger, established firms. Further analysis would be needed to determine if small businesses are involved in the supply chain or as subcontractors.

Oversight & Accountability

Oversight will likely be managed by the Office of Assistant Secretary for Preparedness and Response (ASPR) within HHS. Accountability measures will be tied to the achievement of research milestones and adherence to the Cost Plus Fixed Fee agreement. Transparency will depend on reporting requirements stipulated in the contract, with potential for Inspector General review given the significant federal investment.

Related Government Programs

National Institutes of Health (NIH) Research Grants
Biomedical Advanced Research and Development Authority (BARDA) Contracts
Department of Defense (DoD) Biodefense Research Programs
Centers for Disease Control and Prevention (CDC) Infectious Disease Research

Risk Flags

Potential for cost overruns due to R&D complexity.
Uncertainty in achieving desired antibody efficacy and cross-reactivity.
Long development timelines increase risk of evolving threats.
Dependence on contractor's specialized expertise.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $103.5 million to MODEX THERAPEUTICS, INC. ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA.

Who is the contractor on this award?

The obligated recipient is MODEX THERAPEUTICS, INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $103.5 million.

What is the period of performance?

Start: 2023-09-27. End: 2028-02-29.

What is the specific scientific approach Modex Therapeutics will employ to develop these multispecific antibodies?

The provided data does not detail the specific scientific methodology Modex Therapeutics will utilize. However, the contract's objective is to 'ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES'. This implies a focus on engineering antibodies that can target multiple viral strains or epitopes simultaneously, potentially offering broader protection than traditional single-target antibodies. Techniques could involve antibody engineering platforms, phage display, hybridoma technology, or recombinant DNA methods to create bispecific or trispecific antibodies designed for high affinity and cross-reactivity against conserved regions of SARS-CoV-2 variants and avian influenza viruses. Further details would be found in Modex Therapeutics' technical proposal and subsequent project reports.

How does the $103.5 million contract value compare to other federal investments in pandemic preparedness R&D?

The $103.5 million award to Modex Therapeutics is a significant investment, but it aligns with the scale of federal funding allocated to critical R&D for pandemic preparedness. Agencies like BARDA and NIH frequently award contracts and grants in the tens to hundreds of millions of dollars for the development of vaccines, therapeutics, and diagnostics. For instance, Operation Warp Speed saw billions invested in vaccine development. This specific contract's value is commensurate with the complex, long-term nature of developing novel antibody countermeasures against evolving threats like COVID-19 and avian influenza, suggesting a strategic allocation of resources towards high-impact biodefense.

What are the key performance indicators (KPIs) or milestones for this contract?

The provided summary data does not explicitly list the Key Performance Indicators (KPIs) or specific milestones for this contract. However, for a Cost Plus Fixed Fee research and development contract focused on antibody development, typical milestones would include: successful identification and characterization of lead antibody candidates, demonstration of in vitro potency and cross-reactivity against target viruses, preclinical efficacy studies in relevant animal models, achievement of specific purity and stability targets, and potentially progression towards Investigational New Drug (IND) enabling studies. Performance would be evaluated based on the timely and successful completion of these technical objectives within the allocated budget framework.

What is the track record of Modex Therapeutics in developing similar countermeasures?

Information regarding Modex Therapeutics' specific track record in developing multispecific antibodies for pandemic preparedness is not detailed in the provided contract data. A thorough assessment would require reviewing the company's prior research, publications, existing patents, and any previous government contracts or grants related to infectious disease countermeasures. Their success in securing this significant HHS contract suggests they possess relevant expertise and capabilities, but their specific history with similar complex biological agents and antibody platforms would need independent verification through sources like their corporate website, scientific literature databases, and federal contract databases.

What are the potential risks associated with the Cost Plus Fixed Fee (CPFF) contract type for this project?

The Cost Plus Fixed Fee (CPFF) contract type, while offering flexibility for research and development where costs can be uncertain, carries inherent risks. For the government, the primary risk is that the contractor may have less incentive to control costs rigorously compared to fixed-price contracts, as costs are reimbursed plus a fixed fee. This could lead to cost overruns if not managed effectively through strong government oversight and detailed cost monitoring. For the contractor, the risk lies in accurately estimating the effort required to achieve the fixed fee, potentially underestimating the work and not covering their full costs if the project proves more complex than anticipated. Ensuring clear definition of scope and robust financial oversight are crucial for mitigating these risks.

How will the effectiveness of the developed antibodies be validated?

The validation of the developed antibodies' effectiveness will likely involve a multi-stage process, beginning with in vitro assays to confirm potency, specificity, and cross-reactivity against target viruses (e.g., SARS-CoV-2 variants, avian influenza strains). This would be followed by in vivo studies, likely in animal models, to assess the therapeutic or prophylactic efficacy of the antibodies in preventing or treating infection. The contract's objective to 'ADVANCE THE DEVELOPMENT' suggests progression through preclinical stages. Final validation for human use would require extensive clinical trials (Phase I, II, III) under separate regulatory pathways, which are beyond the scope of this initial R&D contract but represent the ultimate goal.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: BAA-18-100-SOL-0003

Offers Received: 1

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 22 STRATHMORE RD, NATICK, MA, 01760

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $198,470,844

Exercised Options: $103,516,903

Current Obligation: $103,516,903

Actual Outlays: $55,329,053

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline